Literature DB >> 16140943

Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.

Sergei Vatolin1, Ziedulla Abdullaev, Svetlana D Pack, Patrick T Flanagan, Mary Custer, Dmitri I Loukinov, Elena Pugacheva, Julie A Hong, Herbert Morse, David S Schrump, John I Risinger, J Carl Barrett, Victor V Lobanenkov.   

Abstract

Brother of the Regulator of Imprinted Sites (BORIS) is a mammalian CTCF paralog with the same central 11Zn fingers (11ZF) that mediate specific interactions with varying approximately 50-bp target sites. Regulated in vivo occupancy of such sites may yield structurally and functionally distinct CTCF/DNA complexes involved in various aspects of gene regulation, including epigenetic control of gene imprinting and X chromosome inactivation. The latter functions are mediated by meCpG-sensitive 11ZF binding. Because CTCF is normally present in all somatic cells, whereas BORIS is active only in CTCF- and 5-methylcytosine-deficient adult male germ cells, switching DNA occupancy from CTCF to BORIS was suggested to regulate site specificity and timing of epigenetic reprogramming. In addition to 11ZF-binding paternal imprinting control regions, cancer-testis gene promoters also undergo remethylation during CTCF/BORIS switching in germ cells. Only promoters of cancer testis genes are normally silenced in all somatic cells but activated during spermatogenesis when demethylated in BORIS-positive germ cells and are found aberrantly derepressed in various tumors. We show here that BORIS is also expressed in multiple cancers and is thus itself a cancer-testis gene and that conditional expression of BORIS in normal fibroblasts activates cancer-testis genes selectively. We tested if replacement of CTCF by BORIS on regulatory DNA occurs in vivo on activation of a prototype cancer-testis gene, MAGE-A1. Transition from a hypermethylated/silenced to a hypomethylated/activated status induced in normal cells by 5-aza-2'-deoxycytidine (5-azadC) was mimicked by conditional input of BORIS and is associated with complete switching from CTCF to BORIS occupancy at a single 11ZF target. This site manifested a novel type of CTCF/BORIS 11ZF binding insensitive to CpG methylation. Whereas 5-azadC induction of BORIS takes only few hours, derepression of MAGE-A1 occurred 1 to 2 days later, suggesting that BORIS mediates cancer-testis gene activation by 5-azadC. Indeed, infection of normal fibroblasts with anti-BORIS short hairpin RNA retroviruses before treatment with 5-azadC blocked reactivation of MAGE-A1. We suggest that BORIS is likely tethering epigenetic machinery to a novel class of CTCF/BORIS 11ZF target sequences that mediate induction of cancer-testis genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140943     DOI: 10.1158/0008-5472.CAN-05-0858

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  88 in total

1.  Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.

Authors:  Jason A Dubovsky; Daniel Wang; John J Powers; Emmanuel Berchmans; Matthew A Smith; Kenneth L Wright; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Res       Date:  2010-09-22       Impact factor: 3.156

2.  BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.

Authors:  Anna Woloszynska-Read; Smitha R James; Chajoun Song; Boquan Jin; Kunle Odunsi; Adam R Karpf
Journal:  Cancer Immun       Date:  2010-07-23

3.  Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.

Authors:  Adam R Karpf; Suxia Bai; Smitha R James; James L Mohler; Elizabeth M Wilson
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

4.  Investigation of fusion gene expression in HCT116 cells.

Authors:  Yanmei Zhang; Juan Ren; Mengdie Fang; Xiaoju Wang
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

5.  Possible prognostic value of BORIS transcript variants ratio in laryngeal squamous cell carcinomas - a pilot study.

Authors:  Renata Novak Kujundžić; Ivana Grbeša; Mirko Ivkić; Božo Krušlin; Paško Konjevoda; Koraljka Gall Trošelj
Journal:  Pathol Oncol Res       Date:  2014-02-23       Impact factor: 3.201

6.  BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.

Authors:  William C Hines; Alexey V Bazarov; Rituparna Mukhopadhyay; Paul Yaswen
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

7.  Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.

Authors:  Chad A Glazer; Ian M Smith; Michael F Ochs; Shahnaz Begum; William Westra; Steven S Chang; Wenyue Sun; Sheetal Bhan; Zubair Khan; Steven Ahrendt; Joseph A Califano
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

8.  CTCF regulates the local epigenetic state of ribosomal DNA repeats.

Authors:  Suzanne van de Nobelen; Manuel Rosa-Garrido; Joerg Leers; Helen Heath; Widia Soochit; Linda Joosen; Iris Jonkers; Jeroen Demmers; Michael van der Reijden; Verónica Torrano; Frank Grosveld; M Dolores Delgado; Rainer Renkawitz; Niels Galjart; Frank Sleutels
Journal:  Epigenetics Chromatin       Date:  2010-11-08       Impact factor: 4.954

Review 9.  CTCF shapes chromatin by multiple mechanisms: the impact of 20 years of CTCF research on understanding the workings of chromatin.

Authors:  Rolf Ohlsson; Marek Bartkuhn; Rainer Renkawitz
Journal:  Chromosoma       Date:  2010-02-20       Impact factor: 4.316

10.  Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer.

Authors:  Ian M Smith; Chad A Glazer; Suhail K Mithani; Michael F Ochs; Wenyue Sun; Sheetal Bhan; Alexander Vostrov; Ziedulla Abdullaev; Victor Lobanenkov; Andrew Gray; Chunyan Liu; Steven S Chang; Kimberly L Ostrow; William H Westra; Shahnaz Begum; Mousumi Dhara; Joseph Califano
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.